PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

RCT (n=1,945) found similar rates of 5 year progression free survival (PFS) for those given 6 and 8 cycles of eBEACOPP who were PET-2 +ve (after scan after 2 cycles). PFS for those given 4 and 6 cycles of eBEACOPP was also similar in those who were PET-2 –ve.

SPS commentary:

Authors state that the potential reduction from eight to four cycles of eBEACOPP depending on PET-2 scan result represents a benchmark in the treatment of early-responding patients, who can now be potentially cured with a short and safe treatment approach.

The Lancet Haematology